Shares of Bone Biologics Co. (NASDAQ:BBLGW – Get Free Report) fell 0.3% during mid-day trading on Wednesday . The company traded as low as $29.75 and last traded at $31.95. 1,309 shares were traded during mid-day trading, an increase of 77% from the average session volume of 738 shares. The stock had previously closed at $32.05.
Bone Biologics Price Performance
The business’s 50 day moving average is $18.79 and its two-hundred day moving average is $15.10.
About Bone Biologics
Bone Biologics, Inc is a clinical-stage biopharmaceutical company focused on developing protein-based therapeutics designed to promote bone healing and regeneration in acute and chronic orthopedic conditions. Its proprietary platform combines key osteogenic growth factors with engineered delivery matrices to support repair in complex fractures, spinal fusion procedures and non-union bone injuries. By targeting the biology of bone formation, the company aims to overcome limitations associated with autografts, allografts and synthetic implants.
The company’s lead candidate is advancing through preclinical evaluation, with studies assessing efficacy in animal models of fracture repair and spinal arthrodesis.
Read More
- Five stocks we like better than Bone Biologics
- Your Bank Account Is No Longer Safe
- Nvidia CEO Issues Bold Tesla Call
- Buy this Gold Stock Before May 2026
- What a Former CIA Agent Knows About the Coming Collapse
- This $15 Stock Could Go Down as the #1 Stock of 2026
Receive News & Ratings for Bone Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bone Biologics and related companies with MarketBeat.com's FREE daily email newsletter.
